Tempest Therapeutics (TPST) Cash & Equivalents (2011 - 2026)

Tempest Therapeutics has reported Cash & Equivalents for 15 years, with the latest figure at $7.7 million in Q4 2025.

• Quarterly Cash & Equivalents fell 74.54% year-over-year to $7.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.7 million (down 74.54% YoY) and the FY2025 annual result came in at $7.7 million, down 74.54% from the prior year.
• Cash & Equivalents climbed to $7.7 million in Q4 2025 per TPST's latest filing, from $7.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $68.4 million in Q2 2021 and troughed at $7.5 million in Q3 2025.
• A 5-year average of $33.0 million and a median of $31.2 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2025: Cash & Equivalents surged 217.3% in 2021, then slumped 74.54% in 2025.
• Over 5 years, Cash & Equivalents stood at $51.8 million in 2021, then sank by 39.74% to $31.2 million in 2022, then climbed by 25.62% to $39.2 million in 2023, then fell by 22.84% to $30.3 million in 2024, then plunged by 74.54% to $7.7 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $7.7 million, $7.5 million, and $14.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.